

Please amend the claims as follows:

1-4. (Canceled)

5. (Original) An isolated laminin $\alpha 5$ polypeptide, consisting of the amino acid sequence of SEQ ID NO:2.

6. (Original) Isolated laminin 10.

7. (Original) The isolated laminin 10 of claim 6, wherein the isolated laminin 10 is recombinant laminin 10.

8. (Original) The isolated recombinant laminin 10 of claim 7 comprising:
a first chain encoded by a polynucleotide that hybridizes under high stringency conditions to a coding region of one or more sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3;

a second chain encoded by a polynucleotide that hybridizes under high stringency conditions to a coding region of one or more sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:11; and

a third chain encoded by a polynucleotide that hybridizes under high stringency conditions to a coding region of one or more sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19;

wherein the first, second, and third chains are assembled into recombinant laminin 10.

9. (Original) The isolated recombinant laminin 10 of claim 7 comprising:

a first chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:2, and SEQ ID NO:4;

a second chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12; and

a third chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20;

wherein the first, second, and third chains are assembled into recombinant laminin 10.

10. (Original) The isolated recombinant laminin 10 of claim 7 comprising a first, second, and third polypeptide chain, wherein the first, second, and third polypeptide chains each comprise a general structure selected from the group consisting of: (1) R1-R2-R3; (2) R1-R2-R3(e); (3) R3; (4) R3(e); (5) R1-R3; (6) R1-R3(e); (7) R2-R3; and (8) R2-R3(e)

wherein R1 is an amino terminal methionine; R2 is a signal sequence that is capable of directing secretion of the polypeptide, wherein the signal sequence may be the natural signal sequence for the particular laminin chain, that of another secreted protein, or it may be an artificial sequence; R3 is a secreted α 5 laminin chain for the first polypeptide chain, a secreted β 1 laminin chain for the second polypeptide chain, and a secreted γ 1 laminin chain for the third polypeptide chain; and R3(e) is identical to R3, but further comprises an epitope tag.

11-16. (Canceled)

17. Isolated recombinant laminin 10 isolated according to [the] a method comprising [~~of claim 16~~]

a. providing recombinant laminin 10-expressing host cells, wherein the recombinant laminin 10 comprises:

a first chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:2, and SEQ ID NO:4;

a second chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12; and

a third chain comprising a polypeptide at least 70% identical to one or more polypeptide sequences selected from the group consisting of SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20;

wherein the first, second, and third chains are assembled into recombinant laminin 10;

b. growing the cells in cell culture medium under conditions to stimulate expression of the recombinant laminin 10 chains;

c. passing the cell culture medium through an affinity chromatography column, wherein the column contains a compound that binds to the recombinant laminin 10;

d. washing the affinity column to remove unbound materials; and

e. eluting the bound recombinant laminin 10 from the column.

18-22. (Canceled)

23. A pharmaceutical composition comprising:

- a) the isolated laminin 10 of claim 6; and
- b) a pharmaceutically acceptable carrier.

Support for the amendments:

The Applicants have herewith canceled claims 1-4, 11-16, and 18-22 has drawn to non-elected inventions. The Applicants reserve the right to re-file these claims in a subsequent divisional application claiming priority to the present application.

The amendments to claim 17 do not limit the scope of the claim as previously file, but only bring in the limitations of the claims that it was formerly dependent on, in order to put it into independent form.


Election

The Applicants herewith elect the invention of Group II, claims 5-10, 17, and 23 for further prosecution in the present case. The election is made with traverse as the search required for each of the inventive groups extensively overlaps, and thus the required search for the claims as originally filed is not overly burdensome on the patent office.

If the Examiner in the present case has any questions regarding this response, she is invited to contact the below-signed attorney.

Respectfully submitted,

**McDONNELL BOEHNEN
HULBERT & BERGHOFF**



David S. Harper
Reg. No. 42,636

3/19/04